Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80374 |
Name | gastroesophageal cancer |
Definition | A gastrointestinal system cancer that is located_in the proximal esophagus and the distal stomach. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ARID1A mutant | unspecified PD-1 antibody | gastroesophageal cancer | predicted - sensitive | detail... |
ARID1A mutant | unspecified PD-L1 antibody | gastroesophageal cancer | predicted - sensitive | detail... |
PTEN dec exp | Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin | gastroesophageal cancer | no benefit | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | gastroesophageal cancer | not predictive | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | gastroesophageal cancer | not predictive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Active, not recruiting | USA | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | 1 |
NCT03653507 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) | Active, not recruiting | USA | ESP | CAN | 15 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Suspended | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03798626 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | AUT | 11 |
NCT03943004 | Phase I | DFP-14927 | Trial of DFP-14927 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Recruiting | USA | 0 |
NCT04074343 | Phase I | Irinotecan + Trifluridine-tipiracil hydrochloride | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT04147819 | Phase I | BAY2701439 | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Recruiting | USA | 1 |
NCT04209686 | Phase II | Olaparib + Paclitaxel + Pembrolizumab | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | Recruiting | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Recruiting | USA | CAN | 1 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04535401 | Phase I | BAY1895344 + Fluorouracil + Irinotecan + Leucovorin | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | Recruiting | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | Recruiting | USA | CAN | 2 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | CAN | 0 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Recruiting | FRA | 0 |